In April 2017, US FDA allowed marketing of first direct-to-consumer tests that provide risk information for 10 diseases or conditions, including:
A.
Early-onset primary dystonia, a movement disorder involving involuntary muscle contractions and other uncontrolled movements
B.
Factor XI deficiency, a blood clotting disorder, & hereditary thrombophilia, a blood clot disorder
C.
Gaucher disease type 1, an organ and tissue disorder & hereditary hemochromatosis, an iron overload disorder
D.
Glucose-6-Phosphate Dehydrogenase deficiency, also known as G6PD, a red blood cell condition